The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Evolving frontline strategies to reduce relapse in DLBCL
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses evolving approaches to reducing relapse in diffuse large B-cell lymphoma (DLBCL). He highlights how frontline choices such as polatuzumab vedotin plus R-CHP (Pola-R-CHP) and tafasitamab-based combinations can influence subsequent treatment options, while emerging bispecific and combination approaches may further improve outcomes. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
